News

Don’t click on links or attachments unless you’re sure they are legitimate.

ICYMI, this week we had stories about the role of precision medicine for managing melanoma, a debridement drug for severe pediatric burns, roflumilast cream phase 3 results, and an exclusive KOL interview.

Federal AHRQ offers starting point for reducing greenhouse gas emissions.

The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.

In this week’s Pointers with Dr Portela, the 208SkinDoc reviews a video of laser tattoo removal.

Arcutis Biotherapeutics’ roflumilast cream showed higher efficacy compared to vehicle in two phase 3 studies.

MediWound’s debridement drug will provide a safer non-surgical alternative to severe thermal burns for pediatric patients.

Patients prefer virtual appointments for common ailments, but question the quality of care.

ICYMI, this week we had stories about products to help manage acne, a case study on pediatric vitiligo, data results from a hidradenitis suppurativa clinical trial, BCC management, and more.

Will Kirby, DO, FAOCD, and Karan Lal, DO, FAAD, MS, talk about falling in love with medicine, the best dermatology advice ever received, and losing over 100 pounds.

Aerolase launches the Exci308 to help fight common skin conditions.

Organizations that focus on diversity, equity and inclusion are more productive and employees are more satisfied.

At a poster session at the Skin of Color Update meeting in New York City, a study looked at whether women of color thought they were well-represented when it comes to learning about skin aging and prevention.

At the Skin of Color Update 2022 meeting, Pearl Grimes, MD, shares her thoughts on the recent approval of ruxolitinib cream.

Medical experts use common set of criteria to diagnose disease.

Barbara McElroy, MSN, CRNI, VA-BC, discussed best practices for creating an infusion center at the National Infusion Center Association Annual Conference.

DaxibotulinumtoxinA for Injection will provide long-lasting results with fewer injection treatments over time.

New sticky tape study can help predict onset of pediatric atopic eczema in babies.

Arcutis to present data from topical roflumilast clinical program at EADV 2022 Congress.

As we continue to face the COVID-19 pandemic and its long-term consequences, it is more important than ever for providers to build trust with patients.

Move comes after FDA give emergency use authorization for bivalent vaccines.

Sarah Higgins, DNP, APRN, WHNP-BC, discusses the best career advice she ever got, what she believes is the biggest myth in the aesthetic industry, and what changes she would like to see take place in the field of aesthetic dermatology.

ICYMI, this week we had stories about non-prescription acne treatments, clinical study results, pediatric atopic dermatitis, and the EADV 2022 Congress.

Revelle Aesthetics’ cellulite reduction device helps address frustrating aesthetic concerns.

AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.

Topline data expected in the first half of 2023.

Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.

Positioning your portfolio for price stability and growth.

New research by the National Eczema Association has revealed the importance of patient input into treatment decisions.

ICYMI, this week we had stories about adherence issues in acne treatment, shin guard dermatitis, atopic dermatitis in skin of color patients, clinical trial news from Arcutis Biotherapeutics, and more.